{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:16:07Z","timestamp":1784139367254,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s00192-023-05528-y","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T09:03:01Z","timestamp":1681376581000},"page":"2207-2216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The efficacy and safety of medication for treating overactive bladder in patients with Parkinson's disease: a meta-analysis and systematic review of randomized double-blind placebo-controlled trials"],"prefix":"10.1007","volume":"34","author":[{"given":"Bo","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangfeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9810-8145","authenticated-orcid":false,"given":"Zhongbao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,13]]},"reference":[{"issue":"2","key":"5528_CR1","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/mds.21253","volume":"22","author":"K Winge","year":"2007","unstructured":"Winge K, Nielsen KK, Stimpel H, Lokkegaard A, Jensen SR, Werdelin L. Lower urinary tract symptoms and bladder control in advanced Parkinson\u2019s disease: effects of deep brain stimulation in the subthalamic nucleus. Mov Disord. 2007;22(2):220\u20135.","journal-title":"Mov Disord"},{"issue":"3","key":"5528_CR2","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00702-007-0855-9","volume":"115","author":"R Sakakibara","year":"2008","unstructured":"Sakakibara R, Uchiyama T, Yamanishi T, Shirai K, Hattori T. Bladder and bowel dysfunction in Parkinson\u2019s disease. J Neural Transm (Vienna, Austria\u202f: 1996). 2008;115(3):443\u201360.","journal-title":"J Neural Transm (Vienna, Austria : 1996)"},{"issue":"2","key":"5528_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.parkreldis.2010.08.022","volume":"17","author":"S Jain","year":"2011","unstructured":"Jain S. Multi-organ autonomic dysfunction in Parkinson disease. Parkinsonism Relat Disord. 2011;17(2):77\u201383.","journal-title":"Parkinsonism Relat Disord"},{"issue":"2b","key":"5528_CR4","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1590\/S0004-282X2003000300007","volume":"61","author":"RN Campos-Sousa","year":"2003","unstructured":"Campos-Sousa RN, Quagliato E, da Silva BB, de Carvalho Jr RM, Ribeiro SC, de Carvalho DF. Urinary symptoms in Parkinson\u2019s disease: prevalence and associated factors. Arq Neuropsiquiatr. 2003;61(2b):359\u201363.","journal-title":"Arq Neuropsiquiatr."},{"issue":"6","key":"5528_CR5","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/mds.20867","volume":"21","author":"K Winge","year":"2006","unstructured":"Winge K, Fowler CJ. Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord. 2006;21(6):737\u201345.","journal-title":"Mov Disord"},{"issue":"3","key":"5528_CR6","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.nbd.2011.10.002","volume":"46","author":"R Sakakibara","year":"2012","unstructured":"Sakakibara R, Tateno F, Kishi M, Tsuyuzaki Y, Uchiyama T, Yamamoto T. Pathophysiology of bladder dysfunction in Parkinson\u2019s disease. Neurobiol Dis. 2012;46(3):565\u201371.","journal-title":"Neurobiol Dis"},{"issue":"7","key":"5528_CR7","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/iju.12421","volume":"21","author":"R Sakakibara","year":"2014","unstructured":"Sakakibara R, Tateno F, Nagao T, et al. Bladder function of patients with Parkinson\u2019s disease. Int J Urol. 2014;21(7):638\u201346.","journal-title":"Int J Urol"},{"issue":"1","key":"5528_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/nau.23869","volume":"38","author":"S Hajebrahimi","year":"2019","unstructured":"Hajebrahimi S, Chapple CR, Pashazadeh F, Salehi-Pourmehr H. Management of neurogenic bladder in patients with Parkinson\u2019s disease: a systematic review. Neurourol Urodyn. 2019;38(1):31\u201362.","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"5528_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12894-019-0438-8","volume":"19","author":"M Gubbiotti","year":"2019","unstructured":"Gubbiotti M, Giannantoni A, Cantaluppi S, Coluccia AC, Ghezzi F, Serati M. The impact of mirabegron on sexual function in women with idiopathic overactive bladder. BMC Urol. 2019;19(1):7.","journal-title":"BMC Urol"},{"key":"5528_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eururo.2022.01.045","volume":"82","author":"AK Nambiar","year":"2022","unstructured":"Nambiar AK, Arlandis S, B\u00f8 K, et al. European Association of Urology Guidelines on the Diagnosis and Management of Female Non-neurogenic Lower Urinary Tract Symptoms. Part 1: diagnostics, overactive bladder, stress urinary incontinence, and mixed urinary incontinence. Eur Urol. 2022;82:49\u201359.","journal-title":"Eur Urol"},{"key":"5528_CR11","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1177\/03915603221076949","volume":"89","author":"AA Sripad","year":"2022","unstructured":"Sripad AA, Raker CA, Sung VW. Overactive bladder medication: anticholinergics versus mirabegron by specialty. Urologia. 2022;89:511\u20136. https:\/\/doi.org\/10.1177\/03915603221076949.","journal-title":"Urologia."},{"issue":"4","key":"5528_CR12","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/luts.12382","volume":"13","author":"KV Carlson","year":"2021","unstructured":"Carlson KV, Rovner ES, Nair KV, Deal AS, Kristy RM, Hairston JC. Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: findings from the PERSPECTIVE registry study. Lower Urin Tract symptoms. 2021;13(4):425\u201334.","journal-title":"Lower Urin Tract symptoms"},{"key":"5528_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg (London, England). 2021;88: 105906.","journal-title":"Int J Surg (London, England)"},{"key":"5528_CR14","first-page":"Ed000142","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev. 2019;10:Ed000142.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"5528_CR15","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/nau.24552","volume":"40","author":"SY Cho","year":"2021","unstructured":"Cho SY, Jeong SJ, Lee S, et al. Mirabegron for treatment of overactive bladder symptoms in patients with Parkinson\u2019s disease: a double-blind, randomized placebo-controlled trial (Parkinson\u2019s Disease Overactive bladder Mirabegron, PaDoMi Study). Neurourol Urodyn. 2021;40(1):286\u201394.","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"5528_CR16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1080\/21681805.2021.1990994","volume":"56","author":"M Moussa","year":"2022","unstructured":"Moussa M, Chakra MA, Dabboucy B, Fares Y, Dellis A, Papatsoris A. The safety and effectiveness of mirabegron in Parkinson\u2019s disease patients with overactive bladder: a randomized controlled trial. Scand J Urol. 2022;56(1):66\u201372.","journal-title":"Scand J Urol"},{"issue":"8","key":"5528_CR17","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s00345-019-02981-7","volume":"38","author":"T Yonguc","year":"2020","unstructured":"Yonguc T, Sefik E, Inci I, et al. Randomized, controlled trial of fesoterodine fumarate for overactive bladder in Parkinson\u2019s disease. World J Urol. 2020;38(8):2013\u20139.","journal-title":"World J Urol"},{"issue":"5","key":"5528_CR18","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.parkreldis.2015.02.025","volume":"21","author":"TA Zesiewicz","year":"2015","unstructured":"Zesiewicz TA, Evatt M, Vaughan CP, et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2015;21(5):514\u201320.","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"5528_CR19","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/mds.20324","volume":"20","author":"MA Hely","year":"2005","unstructured":"Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson\u2019s disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord. 2005;20(2):190\u20139.","journal-title":"Mov Disord"},{"issue":"11","key":"5528_CR20","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/j.1468-1331.2005.01087.x","volume":"12","author":"K Winge","year":"2005","unstructured":"Winge K, Friberg L, Werdelin L, Nielsen KK, Stimpel H. Relationship between nigrostriatal dopaminergic degeneration, urinary symptoms, and bladder control in Parkinson\u2019s disease. Eur J Neurol. 2005;12(11):842\u201350.","journal-title":"Eur J Neurol"},{"issue":"1","key":"5528_CR21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4081\/aiua.2022.1.107","volume":"94","author":"M Moussa","year":"2022","unstructured":"Moussa M, Abou Chakra M, Papatsoris AG, et al. Perspectives on the urological care in Parkinson\u2019s disease patients. Arch Ital Urol Androl. 2022;94(1):107\u201317.","journal-title":"Arch Ital Urol Androl."},{"issue":"1","key":"5528_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cger.2019.09.011","volume":"36","author":"J Margolesky","year":"2020","unstructured":"Margolesky J, Bett\u00e9 S, Singer C. Management of urologic and sexual dysfunction in Parkinson disease. Clin Geriatr Med. 2020;36(1):69\u201380.","journal-title":"Clin Geriatr Med"},{"issue":"9","key":"5528_CR23","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11934-014-0435-0","volume":"15","author":"AV Badri","year":"2014","unstructured":"Badri AV, Purohit RS, Skenazy J, Weiss JP, Blaivas JG. A review of lower urinary tract symptoms in patients with Parkinson\u2019s disease. Curr Urol Rep. 2014;15(9):435.","journal-title":"Curr Urol Rep"},{"issue":"1","key":"5528_CR24","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/nau.24817","volume":"41","author":"AJ Seinen","year":"2022","unstructured":"Seinen AJ, Elburg R, Hollegien LM, Blanker MH, Witte LPW. The patient pathway for overactive bladder management: a quantitative analysis. Neurourol Urodyn. 2022;41(1):290\u20135.","journal-title":"Neurourol Urodyn"},{"key":"5528_CR25","doi-asserted-by":"publisher","first-page":"175628641984345","DOI":"10.1177\/1756286419843458","volume":"12","author":"M Gubbiotti","year":"2019","unstructured":"Gubbiotti M, Conte A, Di Stasi SM, Tambasco N, Giannantoni A. Feasibility of mirabegron in the treatment of overactive bladder in patients affected by Parkinson\u2019s disease: a pilot study. Ther Adv Neurol Disord. 2019;12:1756286419843458.","journal-title":"Ther Adv Neurol Disord"},{"key":"5528_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.parkreldis.2018.07.005","volume":"57","author":"B Peyronnet","year":"2018","unstructured":"Peyronnet B, Vurture G, Palma JA, et al. Mirabegron in patients with Parkinson disease and overactive bladder symptoms: a retrospective cohort. Parkinsonism Relat Disord. 2018;57:22\u20136.","journal-title":"Parkinsonism Relat Disord"},{"key":"5528_CR27","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1016\/j.jfma.2022.04.004","volume":"121","author":"SF Chen","year":"2022","unstructured":"Chen SF, Chuang YC, Wang CC, Liao CH, Kuo HC. Therapeutic efficacy and cognitive adverse events of overactive bladder medication in patients with central nervous system disorders-a cohort study. J Formos Med Assoc. 2022;121:2101\u20138.","journal-title":"J Formos Med Assoc"},{"issue":"11","key":"5528_CR28","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/s41585-021-00504-x","volume":"18","author":"B Welk","year":"2021","unstructured":"Welk B, Richardson K, Panicker JN. The cognitive effect of anticholinergics for patients with overactive bladder. Nat Rev Urol. 2021;18(11):686\u2013700.","journal-title":"Nat Rev Urol"},{"issue":"12","key":"5528_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260980","volume":"16","author":"J Nagai","year":"2021","unstructured":"Nagai J, Ishikawa Y. Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database. PLoS ONE. 2021;16(12): e0260980.","journal-title":"PLoS ONE"},{"issue":"2","key":"5528_CR30","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1136\/jnnp.2009.186239","volume":"81","author":"U Ehrt","year":"2010","unstructured":"Ehrt U, Broich K, Larsen JP, Ballard C, Aarsland D. Use of drugs with anticholinergic effect and impact on cognition in Parkinson\u2019s disease: a cohort study. J Neurol Neurosurg Psychiatry. 2010;81(2):160\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"5528_CR31","doi-asserted-by":"publisher","first-page":"72","DOI":"10.5770\/cgj.25.530","volume":"25","author":"J Heesakkers","year":"2022","unstructured":"Heesakkers J, Te Dorsthorst M, Wagg A. Safety and tolerability of fesoterodine in older adult patients with overactive bladder. Can Geriatr J: CGJ. 2022;25(1):72\u20138.","journal-title":"Can Geriatr J: CGJ"},{"issue":"1","key":"5528_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40520-015-0359-7","volume":"28","author":"A Collamati","year":"2016","unstructured":"Collamati A, Martone AM, Poscia A, et al. Anticholinergic drugs and negative outcomes in the older population: from biological plausibility to clinical evidence. Aging Clin Exp Res. 2016;28(1):25\u201335.","journal-title":"Aging Clin Exp Res"},{"key":"5528_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinane.2019.109632","volume":"61","author":"A Mueller","year":"2020","unstructured":"Mueller A, Spies CD, Eckardt R, et al. Anticholinergic burden of long-term medication is an independent risk factor for the development of postoperative delirium: a clinical trial. J Clin Anesth. 2020;61: 109632.","journal-title":"J Clin Anesth"},{"issue":"1","key":"5528_CR34","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s13054-015-1060-0","volume":"19","author":"AN Gosselt","year":"2015","unstructured":"Gosselt AN, Slooter AJ, Boere PR, Zaal IJ. Risk factors for delirium after on-pump cardiac surgery: a systematic review. Crit Care (London, England). 2015;19(1):346.","journal-title":"Crit Care (London, England)"},{"issue":"9","key":"5528_CR35","doi-asserted-by":"publisher","first-page":"737","DOI":"10.2165\/11592240-000000000-00000","volume":"28","author":"AG Catic","year":"2011","unstructured":"Catic AG. Identification and management of in-hospital drug-induced delirium in older patients. Drugs Aging. 2011;28(9):737\u201348.","journal-title":"Drugs Aging"},{"issue":"2","key":"5528_CR36","doi-asserted-by":"publisher","first-page":"169","DOI":"10.7326\/0003-4819-107-2-169","volume":"107","author":"EB Larson","year":"1987","unstructured":"Larson EB, Kukull WA, Buchner D, Reifler BV. Adverse drug reactions associated with global cognitive impairment in elderly persons. Ann Intern Med. 1987;107(2):169\u201373.","journal-title":"Ann Intern Med"},{"issue":"10","key":"5528_CR37","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1176\/ajp.149.10.1393","volume":"149","author":"L Tune","year":"1992","unstructured":"Tune L, Carr S, Hoag E, Cooper T. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry. 1992;149(10):1393\u20134.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"5528_CR38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.neulet.2007.02.015","volume":"417","author":"K Plaschke","year":"2007","unstructured":"Plaschke K, Thomas C, Engelhardt R, et al. Significant correlation between plasma and CSF anticholinergic activity in presurgical patients. Neurosci Lett. 2007;417(1):16\u201320.","journal-title":"Neurosci Lett"},{"issue":"1","key":"5528_CR39","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/jgs.13206","volume":"63","author":"MS Salahudeen","year":"2015","unstructured":"Salahudeen MS, Hilmer SN, Nishtala PS. Comparison of anticholinergic risk scales and associations with adverse health outcomes in older people. J Am Geriatr Soc. 2015;63(1):85\u201390.","journal-title":"J Am Geriatr Soc"}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-023-05528-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00192-023-05528-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-023-05528-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T14:03:52Z","timestamp":1695045832000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00192-023-05528-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,13]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["5528"],"URL":"https:\/\/doi.org\/10.1007\/s00192-023-05528-y","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"value":"0937-3462","type":"print"},{"value":"1433-3023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,13]]},"assertion":[{"value":"17 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}